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Nitric oxide and arterial disease
Joel E. Barbato, MD, and Edith Tzeng, MD, Pittsburgh, Pa
Nitric oxide (NO) is a molecule that has gained recognition as a crucial modulator of vascular disease. NO has a number
of intracellular effects that lead to vasorelaxation, endothelial regeneration, inhibition of leukocyte chemotaxis, and
platelet adhesion. Its role in vascular disease has been intensively investigated and further elucidated over the past two
decades. It is important in the pathogenesis of many cardiovascular diseases, including atherosclerosis, intimal hyperpla-
sia, and aneurysmal disease. In addition, NO has been used as a therapeutic tool to treat diseases that range from recurrent
stenosis to inhibiting thrombotic events. Many commonly used medications have their therapeutic actions through the
production of NO. This review highlights the vascular biologic characteristics of NO, its role in the pathogenesis of
cardiovascular disease processes, and its potential therapeutic applications. (J Vasc Surg 2004;40:187-93.)Nitric oxide (NO) is a molecule that has gained increas-
ing attention in the vascular community since being named
Science magazine’s “Molecule of the Year” in 1992, fol-
lowed by the awarding of the Nobel Prize in Physiology
and Medicine in 1998 to Drs Robert F. Furchgott, Louis J.
Ignarro, and Ferid Murad “for their discoveries concerning
nitric oxide as a signaling molecule in the cardiovascular
system.” Over the past two decades the vascular actions of
NO have been investigated intensively. Here we review the
biologic characteristics of NO as it relates to the cardiovas-
cular system, disorders of NO metabolism as they relate to
specific clinical disorders, and the potential vascular clinical
applications of this elusive molecule.
BIOLOGIC CHARACTERISTICS OF NO
NO is a gas with a half-life of several seconds. It is
synthesized by a family of NO synthase (NOS) enzymes
that produce NO and citrulline through a five-electron
oxidation of the guanidine-nitrogen terminal of L-arginine.
Three distinct isoforms of NOS have been identified in
human beings and other organisms. Two of these are
constitutively expressed: neuronal NOS (nNOS; also
known as NOS-1, because it was the first isoform discov-
ered) and endothelial NOS (eNOS; NOS-3). Both of these
are regulated by calcium and calmodulin and by post-
translational modifications of the enzymes. The third iso-
form is inducible NOS (iNOS; NOS-2). It is regulated by
cytokine stimulation, and produces quantities of NO far
exceeding those produced by the other two isoforms.
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tion, including tetrahydrobiopterin (BH4), nicotinamide-
adenine-dinucleotide phosphate (NADPH), flavin adenine
dinucleotide, and flavin mononucleotide. (For a full bibli-
ography, see Appendix, online only.)
NOS enzymes are expressed by a variety of cell types.
eNOS has been identified in endothelial and smooth mus-
cle cells (SMCs), cardiac myocytes, bone cells, and neurons.
nNOS has been found in neurons, skeletal muscle, the
pancreas, and the kidneys. iNOS can be expressed in almost
any cell type under cytokine stimulation, but is also consti-
tutively expressed in some tissues such as the bowel wall.
The list of tissues and cells that can express any or all of
these NOS isoforms continues to grow, which supports the
importance of NO in a variety of physiologic and patho-
physiologic processes.
The first realization that NO was pivotal in biologic
processes occurred when it was identified as endothelium-
derived relaxing factor (EDRF). In 1980 EDRF was de-
scribed as a factor that mediates vasodilation and is released
by the vascular endothelium in response to acetylcholine.
Independent work conclusively revealed that NO had iden-
tical properties and characteristics as those of EDRF. Since
these early works, NO has been further characterized and
found to possess a number of physiologic functions essen-
tial to vascular homeostasis (Fig).
The molecular signaling pathways through which NO
transmits its message are many, and are still being eluci-
dated. However, one prevalent pathway in the vasculature
involves the activation of soluble guanylyl cyclase, which
then produces cyclic GMP (cGMP). cGMP appears to be
the second messenger responsible for mediating vasorelax-
ation and antiplatelet functions. NO inhibits SMC prolif-
eration and migration through cGMP, although cGMP-
independent pathways for these actions also have been
found. NO can also act directly on calcium-dependent
potassium channels, leading to the relaxation of smooth
muscle. The vasoprotective effects of NO extend beyond187
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liferation, protection of endothelial cells from apoptosis,
and inhibition of adherence of inflammatory cells.
DISEASE PROCESSES
Atherosclerosis. Atherosclerosis is the number 1
cause of morbidity and mortality in the United States. It
involves a cascade of pathologic processes that culminate in
vascular lesion development and the consequences of re-
duced tissue perfusion, such as myocardial infarction and
limb loss. Once atherosclerotic lesions have developed,
plaque composition determines its predilection for rupture
and subsequent ischemic events. In 1986, it was reported
that acetylcholine induces vasodilation in the coronary
vessels of healthy patients without atherosclerosis, but not
in patients with angiographic evidence of atherosclerosis.
Since then it has clearly been shown that not only is there
impaired endothelial production of and vascular response
to NO in atherosclerosis, but NO also plays a crucial part in
the development of these lesions.
One of the earliest processes identifiable in the devel-
opment of atherosclerosis is endothelial dysfunction. The
elaboration of NO is crucial to the normal homeostatic
function of the endothelium. Patients with developing
atherosclerosis have reduced NO bioavailability in both the
coronary and peripheral vasculature. The importance of
NO in atherogenesis was suggested in mice deficient in
apolipoprotein E (apoE), in which atherosclerotic lesions
developed spontaneously when eNOS was also deleted.
Compared with ApoE knockout mice, ApoE-eNOS dou-
ble-knockout mice showed accelerated atherosclerotic
Summary of vasculaplaque formation. Similarly, NOS inhibition in ApoE
knockout mice increased atherogenesis. The overexpres-
sion of eNOS in transgenic mice leads to a decrease in
blood pressure and plasma cholesterol levels, and a 40%
reduction in atherosclerotic lesion formation. However,
evidence also suggests that NO may be involved in athero-
genesis. ApoE-iNOS double-knockout mice demonstrate
reduced atherosclerotic plaque formation. This suggests
that NO derived from eNOS may protect the vasculature
from atherosclerosis, whereas NO from iNOS may pro-
mote lesion formation.
The understanding of the pathogenesis of atheroscle-
rosis has evolved substantially over the last several decades.
It is now clear that inflammatory mediators, in addition to
endothelial dysfunction, are intimately involved in this
process. After the initial endothelial dysfunction and re-
duced NO levels, a pro-inflammatory phenotype is seen in
animals predisposed to atheromatous plaque formation,
with increased neutrophil adherence. Processes involved in
the generation of oxidative stress, such as the generation of
superoxide anion, are activated, leading to cellular injury
and peroxidation of lipid components. This produces oxi-
dized low-density lipoproteins (LDLs), which are key me-
diators of atherosclerosis.
A number of specific factors can alter the production of
NO and therefore influence the progression of atheroscle-
rosis. BH4 is a necessary cofactor for the proper functioning
of all NOS enzymes. When it is in short supply within the
cell, NOS uncouples and behaves as an NADPH oxidase,
leading to production of superoxide rather than NO. Vita-
min C exerts beneficial effects on the cardiovascular system
cts of nitric oxide.r effe
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centrations of BH4. Supplementation with BH4 in apoE-
deficient mice increases eNOS activity, but does not affect
iNOS activity. Recent studies have also demonstrated the
cardiovascular protection afforded by folate supplementa-
tion, with a trend toward increased basal NO production
and improvement in endothelial function. Folate can aug-
ment BH4 biosynthesis and increase NOS activity, provid-
ing endothelial protection against development of athero-
sclerosis.
Hypercholesterolemia and hyperlipidemia contribute
to atherosclerotic plaque formation. These molecules me-
diate endothelial dysfunction, in part by consuming NO
and forming reactive oxygen species that further damage
the vasculature. Pharmacologic reduction of plasma choles-
terol and lipid concentrations can reduce lesion formation
by preventing consumption of NO. These medications
work to reduce lipid levels through inhibition of 5-hy-
droxy-3-methylglutaryl coenzyme A reductase activity.
They also have a direct effect on eNOS activity, increasing
expression of the enzyme and subsequent NO synthesis.
Alternatively, statin agents can help decrease nitrotyrosine-
bound proteins (a toxic breakdown product of NO) and
decrease the progression of atherosclerosis.
A number of other factors also contribute to the pro-
gression of plaque formation. Oxidized lipids (eg, oxidized
LDL) can displace eNOS from its position in the intracel-
lular caveolae and therefore disrupt eNOS activity. This
interference with eNOS can be prevented by elevating
high-density lipoprotein levels, which can fully restore
eNOS activity. Oxidized lipids also consume NO within the
vessel wall, resulting in nuclear factor B activation and
setting into motion a number of inflammatory mediators.
Of interest, human beings have endogenous NOS inhibi-
tors, including N-monomethyl-L-arginine and asymmet-
ric dimethylarginine (ADMA), the latter being more prev-
alent in plasma. ADMA levels are elevated in both animals
and human beings with hypercholesterolemia, and in the
setting of peripheral occlusive disease. Increasing the L-
arginine–ADMA ratio in patients with intermittent claudi-
cation by administration of L-arginine increased pain-free
walking intervals by more than 200% and absolute walking
distance by 150% over control. Therefore finding ways to
decrease ADMA levels may prove efficacious in attempts to
limit atherosclerotic lesion progression.
Diabetic vascular disease. Diabetes mellitus is not
itself a vascular disease; however, the pathophysiologic
mechanisms behind development of vascular disease are
accentuated in diabetes. Diabetes affects more than 150
million persons worldwide, greater than 90% of whom have
type II, or non-insulin-dependent diabetes. These patients
with type II diabetes constitute a large percentage of pa-
tients with advanced cardiovascular disease. They have a
more aggressive form of arterial disease than do their coun-
terparts without diabetes, and also respond less favorably to
a variety of vascular interventions, with higher morbidity
and poorer outcomes after angioplasty and bypass surgery.
In patients with diabetes, neointimal areas develop morethan twofold that in patients without diabetes after angio-
plasty and stent placement. Recent trials have demonstrated
that reversing the metabolic derangements of diabetes,
including hyperglycemia, hyperlipidemia, and hyperten-
sion, can reduce cardiovascular complications by as much as
50%.
One of the hallmarks of diabetes mellitus is dysfunction
of the endothelium and SMCs, the major components of
the blood vessel wall. A number of studies have correlated
this dysfunction with impaired production or reduced bio-
availability of NO. Impaired vasodilation after brachial
artery infusions of sodium nitroprusside, an exogenous NO
donor, and methacholine chloride, a stimulator of endo-
thelium-derived NO, in patients with diabetes suggests that
there is both impaired release of NO in response to agonists
and impaired response to exogenously delivered NO in
these patients. Similarly, impaired relaxation to NO donors
has also been documented in the coronary circulation in
patients with type II diabetes at intravascular ultrasound
scanning.
Emerging data show that not only is the production of
NO crucial in the maintenance of vascular integrity, but the
availability of NO and the local redox state of the vessel also
have important roles. Vessels in patients with diabetes have
an increased concentration of advanced glycation end prod-
ucts, their corresponding receptor, and oxidized LDLs, all
of which can consume locally produced NO and limit its
bioavailability. Diabetes and chronic hyperglycemia also
lead to augmented superoxide production. Superoxide can
react with NO to produce peroxynitrite, which is cytotoxic,
proinflammatory, and can contribute to further vascular
damage and dysfunction.
Of interest, a number of medications used in the man-
agement of diabetes have beneficial effects on the vascula-
ture through NO. The thiazolidinediones, including ros-
iglitazone, are a class of potent insulin-sensitizing agents
used in the treatment of type II diabetes mellitus. These
medications act through peroxisome proliferators–acti-
vated receptor-, a transcription factor that regulates lipid
and glucose metabolism. In mice, these drugs increase NO
availability by decreasing NADPH oxidase activity and
thereby decreasing superoxide production and reducing
the quenching effect on NO. Despite its pro-proliferative
effects on SMCs, insulin can also exert anti-inflammatory
effects, in part through NO-mediated down-regulation of
intracellular adhesion molecule-1 expression in endothelial
cells. Furthermore, insulin activates the phosphatidylinosi-
tol-3 kinase pathway to stimulate eNOS synthesis of NO.
Angiotensin II can increase generation of reactive oxygen
species and oppose the local action of NO. Angiotensin
converting enzyme inhibitors may be vasoprotective by
decreasing this superoxide production, increasing NO
availability and decreasing ADMA concentrations.
Aneurysms. Aneurysmal degeneration of the blood
vessel wall presents a formidable diagnostic and therapeutic
dilemma for those who care for patients with vascular
disease. The development of aneurysms has been an intense
area of research, because surveillance programs have proven
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at risk has taken on an even more important role in this
disease process. Increasingly it has become clear that NO
has an important role in the pathogenesis of aneurysm
formation.
Experimental models of aortic aneurysm formation
lend insight into the potential causes of aneurysmal degen-
eration of the vascular wall. One of the more commonly
used methods in animal models for creating aneurysmal
dilatation of the aorta is elastase infusion. In a rat model,
elastase infusion results in aneurysm formation and in-
creased iNOS and matrix metalloproteinase-9 expression in
the aortic wall at days 1 and 7, respectively. Along with
iNOS, a variety of other genes involved with oxidative stress
are up-regulated. NOS inhibition with N(G)-nitro-L-argi-
nine methyl ester (L-NAME) or aminoguanidine signifi-
cantly reduced aortic dilatation in response to elastase. In a
similar murine model, eNOS and nNOS were down-regu-
lated in the aorta after elastase infusion, with a concomitant
increase in iNOS located predominantly within the inflam-
matory cells. iNOS knockout mice, however, had a similar
extent of aneurysm formation after elastase treatment com-
pared with wild-type controls, suggesting that iNOS is not
essential for aneurysm formation in this experimental
model.
Understanding the role of NO in the formation of
aneurysms is much more difficult in human beings, because
the pathogenesis is poorly understood and experimental
models with elastase perfusion are clearly different from the
human condition. Some information can be gleaned from
the available data in human beings, however. Patients with
abdominal aortic aneurysms have impaired endothelium-
dependent and endothelium-independent vasodilation de-
spite elevated serum nitrate levels. Of interest, these pa-
tients also have moderately decreased ADMA levels. Aortic
specimens from patients undergoing elective aortic aneu-
rysm repair confirmed the presence of iNOS in the medial
and adventitial layers of the wall. iNOS was confined largely
to B and T lymphocytes, macrophages, and SMCs. Nitro-
tyrosine, the reaction product of peroxynitrite and proteins,
was also found within the macrophages and smooth muscle
of the aneurysm tissue, which suggests the presence of
cytotoxic reactive nitrogen species. No iNOS expression or
staining for nitrotyrosine was found in normal aortic tissue.
These findings support that iNOS is a component of the
inflammatory process involved in aneurysm formation.
However, it is still unclear whether iNOS-derived NO is
directly responsible for vascular degeneration or whether it
is merely a bystander within the inflammatory cells local-
ized within the aneurysm wall.
Intimal hyperplasia. Intimal hyperplasia is an exuber-
ant healing process that occurs in the vessel wall after injury
limiting the patency rates of vascular interventions, includ-
ing bypass grafts, stents, and balloon angioplasty. Five-year
patency rates for femoropopliteal disease treated with per-
cutaneous transluminal angioplasty range from 38% to
70%, and with bypass range from 65% to 80%. Intimal
hyperplasia is a complex process characterized by loss ordysfunction of the vascular endothelium, proliferation and
migration of SMCs, and a local inflammatory reaction with
recruitment of inflammatory cells and circulating myofibro-
blast precursors. These events all contribute to the progres-
sive obliteration of the vessel lumen. Despite intensive
investigation, no pharmacologic agent has been developed
that can reliably inhibit intimal hyperplasia and improve the
outcomes of vascular interventions.
The pathogenesis of intimal hyperplasia is intimately
linked to loss of local NO synthesis. The initiating event is
endothelial denudation. Loss of the endothelium results in
loss of endothelium-derived NO production and the atten-
dant loss of its homeostatic function. This opens the door
for platelet aggregation, inflammatory cell infiltration, and
SMC proliferation and migration. Intimal hyperplasia oc-
curs after a variety of interventions, including balloon an-
gioplasty, at the sites of vascular anastomoses, and within
and at the edges of vascular stents. One of the major
limitations of endovascular stents has been development of
in-stent recurrent stenosis. Patients with impaired endothe-
lium-derived NO production have higher rates of in-stent
stenosis. Patients with genetic mutation of the eNOS en-
zyme have higher rates of cardiac death after coronary stent
placement, and higher rates of in-stent stenosis.
THERAPEUTIC APPLICATIONS OF NO
Inhibition of intimal hyperplasia. Because the loss
of local endothelial NO production has an important role in
the development of neointimal lesions, it logically follows
that restoration of NO or even providing supraphysiologic
levels of NO to sites of vascular injury may inhibit intimal
hyperplasia. Some of the methods used to augment NO
production in attempting to prevent intimal hyperplasia
formation are summarized in the Table. Early studies
showed that supplementation of the NOS substrate L-
arginine in rodent models of vascular injury significantly
inhibited intimal hyperplasia. Subsequent studies were per-
formed with systemic administration of NO donor com-
pounds, which blocked intimal hyperplasia by 70% to 80%
in rodent models of vascular injury. Even NO delivered via
inhalation reduced neointima formation in rodents, but
required NO administration for the duration of the
experiment.
Few studies have looked directly at the effect of NO or
NO donors on the prevention of intimal hyperplasia in
human beings. One such study, however, was ACCORD
(Action to Control Cardiovascular Risk in Diabetes), in
which 700 patients undergoing elective percutaneous
transluminal coronary angioplasty were randomized to re-
ceive either NO donors (infusion of linsidomine followed
by oral molsidomine) or calcium channel blockers for 6
months. While no improvement was documented in clini-
cal outcomes such as death, nonfatal myocardial infarction,
or need for repeat procedures, there was a reduction in
recurrent stenosis rate (defined as 50% stenosis), from
47% to 38%, in patients who received the NO donors.
The systemic effects of NO are not fully understood at
this time, and the potential for systemic hypotension with
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for local inhibition of intimal hyperplasia is of real concern.
With the advent of gene transfer technologies, the potential
for localized NO delivery became a reality. The first pub-
lished study exploring NOS gene therapy used modified
liposomes to express eNOS within injured rat carotid arter-
ies and demonstrated a 70% reduction in intimal hyperpla-
sia and restoration of vasoresponsiveness to endothelium-
dependent vasodilators.
Since that landmark study, many other studies have also
demonstrated successful inhibition of neointima formation
with NOS gene transfer with eNOS, nNOS, and iNOS.
Most studies have been performed with iNOS. The greater
specific activity of iNOS gives it a theoretical advantage
over eNOS and nNOS, and may allow lower titers of
vectors to be used, thereby averting toxicity. This is an
important consideration, because one of the greatest limi-
tations of gene transfer technologies is the ability to express
sufficient levels of therapeutic product without using toxic
quantities of vector. Adenovirus-mediated iNOS gene
transfer to balloon-injured rat carotid arteries inhibited
intimal hyperplasia by 98% with an extremely low dose of
viral vector, which supports this potential advantage of
iNOS. Subsequent studies in pigs showed that iNOS gene
transfer inhibited intimal hyperplasia by 55% in injured iliac
arteries and 30% within vein bypass grafts. It was also
effective in a pig model of coronary angioplasty and stent-
ing, in which in-stent stenosis was reduced by almost 40%.
With the surge in endovascular techniques for treating
vaso-occlusive disease, methods to reduce in-stent recur-
rent stenosis have been intensively investigated by industry.
Various methods used to examine the therapeutic effect of
Form of NO
Percent
inhibition
of IH Species Model
L-Arginine 39 Rabbit Balloon angioplasty
NO-albumin 77 Rabbit Balloon angioplasty
NO 43 Rat Balloon angioplasty
NO donor 18 Human Coronary angioplast
L-Arginine 37 Rabbit Iliac injury
Adenoviral
eNOS
72 Rat Balloon angioplasty
Adenoviral
iNOS
95 (rat)
52(pig)
Rat/pig Balloon angioplasty
Adenoviral
eNOS
28 Pig Coronary angioplast
NO-releasing
aspirin
23 Mouse Balloon angioplasty
NO-eluting
stent
0 Pig Stent deployment
Adenoviral
iNOS
37 Pig Coronary angioplast
with stent
NO donor 0 Human Coronary angioplast
NO donor 46 Pig Coronary angioplast
NO-eluting
stent
32 Rabbit Stent deployment
NO, Nitric oxide; IH, intimal hyperplasia.Rapamycin and paclitaxel-coated stents have recently been
proven to limit in-stent stenosis, and there are several
encouraging studies that have used NO in a similar fashion.
NO eluting stents exert a local biologic effect on the
stented vessel, including increasing cGMP levels, but ini-
tially failed to prevent in-stent stenosis in a porcine model.
More recently, however, in-stent stenosis was reduced by
32% in a rabbit model with a stent coated with a biodegrad-
able polymer with NO-releasing capacity. Overexpression
of the human RAD50 gene, a DNA repair protein, via gene
transfer in a porcine stent model also prevents in-stent
stenosis through a NO-dependent mechanism. These re-
sults certainly provide promise for the use of NO-eluting
stents and NOS gene transfer to inhibit intimal hyperplasia.
Therapeutic angiogenesis. While prevention of inti-
mal hyperplasia is a major focus of biomedical investiga-
tions, therapies aimed at promoting angiogenesis have re-
ceived equal or greater attention over the past decade. A
significant number of patients with peripheral limb isch-
emia and myocardial ischemia represent excessive operative
risk. Others have diffuse disease not amenable to angio-
plasty or bypass techniques. These patients require tech-
niques that generate new blood supply from the existing
vasculature for end-organ salvage.
Angiogenesis involves the generation of new capillaries
from preexisting vessels. It is intimately tied to the prolif-
eration and differentiation of endothelial cells and the
interaction with their extracellular matrix. A number of
growth factors, the most prominent being vascular endo-
thelial growth factor (VEGF), regulate this process at the
biochemical level, and can stimulate generation of new
on the process of neointimal hyperplasia
Time
period Method of delivery Reference/year
2 wk Oral McNamara et al1 1993
2 wk Local Marks et al2 1995
2 wk Inhaled Lee et al3 1996
6 mo Oral Lablanche et al4 1997
4 wk Local Schwarzacher et al5
1997
2 wk Local gene transfer Janssens et al6 1998
6 wk (rat) Local gene transfer Shears et al7 1998
21 d (pig)
28 d Local gene transfer Varenne et al8 1998
21 d Oral Napoli et al9 2001
28 d Eluting stent Yoon et al10 2002
28 d Local gene transfer Wang et al11 2003
6 mo Oral Wohrle et al12 2003
8 wk Local Harnek et al13 2003
28 d Eluting stent Do et al14 2004NO
y
y
y
y
y
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cally needed blood flow.
NO is intimately involved in angiogenesis. eNOS gene
transfer induced angiogenesis in animal models of hind
limb ischemia in which the arterial flow to the lower limb
had been ligated. This increase in limb blood flow induced
by NOS gene transfer was abrogated with administration of
the NOS inhibitor L-NAME, which indicates that the
beneficial effect was mediated by NO synthesis. Further-
more, these animals were found to have up-regulated
VEGF expression in the ischemic limbs. Similar findings
have been reported in a stroke model in which NO donors
were administered in rats after embolic stroke. These ani-
mals exhibited greater angiogenesis compared with control
animals, mediated through the NO-cGMP pathway.
Many growth factors are involved in angiogenesis, the
most important of which may be VEGF. VEGF stimulates
angiogenesis through an increase in eNOS-mediated NO
production within the endothelium both in vivo and in
culture. Another key growth factor is fibroblast growth
factor (FGF). FGF also functions through a NO-dependent
pathway. NO appears to be crucial for FGF-induced endo-
thelial tube formation, an early process in angiogenesis.
There is currently no Food and Drug Administration–
approved protocol for use of NOS gene therapy to induce
angiogenesis. There are, however, a number of protocols
involving other growth factors to stimulate angiogenesis,
either in peripheral ischemia or inoperable myocardial isch-
emia. The first use of gene therapy for this indication was
reported in 1996 when VEGF plasmid DNA was adminis-
tered intramuscularly in a single patient with lower extrem-
ity ischemia. Since then, more than a dozen clinical trials of
VEGF gene transfer have been performed, with successful
generation of new collateral circulation within ischemic
extremities and within the ischemic myocardium. The most
common adverse event has been development of transient
edema. Similar angiogenesis trials have been performed
with FGF, with comparable results. Because the angiogenic
effect of VEGF appears to be mediated by NO, there are
likely to be further attempts to use the NOS enzyme as a
targeted means to induce vessel growth in ischemic tissues.
Anti-thrombotic agents. Limb ischemia and bypass
graft occlusion often result from acute thrombotic events.
NO has a number of effects on thrombosis and the coagu-
lation system. NO is generated not only in the vessel wall,
but also within circulating platelets, which possess NOS.
NO can have direct effects on platelets, causing a decease in
platelet aggregation and adhesion through an increase in
platelet-derived cGMP. Therefore patients with injured or
dysfunctional endothelium, such as those with atheroscle-
rosis, are affected disproportionately with thrombotic
events. The conventional treatments of these events include
anticoagulation therapy, administration of thrombolytic
agents, and surgical intervention.
A number of investigators have used NO to modulate
thrombosis under experimental conditions. Gene transfer
of C-type natriuretic peptide, a secreted polypeptide, re-
duced neointima formation and thrombosis in a rabbitcarotid injury model. The beneficial effect of C-type natri-
uretic peptide was associated with induction of iNOS.
Others have used eNOS and iNOS gene transfer to inhibit
thrombosis in similar models. Alternatively, blocking NOS
function with inhibitors such as L-NAME can induce mi-
crovessel and macrovessel thrombosis, in part through
angiotensin II–induced tissue factor expression in the en-
dothelium and generation of superoxide. Infusion of the
NO precursor L-arginine inhibits activation of the coagu-
lation cascade in human beings, increasing bleeding time,
prothrombin time, and activated partial thromboplastin
time.
Two common pharmacologic agents used to inhibit
thrombosis, aspirin and cilostazol, act in part through NO.
The beneficial effect of aspirin on cardiac mortality and
stroke has largely been attributed to its anti-platelet activity
mediated by the irreversible inhibition of platelet cycloox-
ygenase and thromboxane formation. Aspirin, however,
also has a number of protective effects on the endothelium.
These effects appear to be mediated through eNOS.
Cilostazol, used in the treatment of claudication, is a phos-
phodiesterase III inhibitor. It has an endothelium-depen-
dent vasorelaxant effect in rat thoracic aorta preconstricted
with phenylephrine. This effect was abrogated in the pres-
ence of NOS inhibition. Cilostazol possesses vasorelaxant
properties in the coronary circulation, a phenomenon at-
tributable to the actions of NO. It has been used clinically
to inhibit recurrent stenosis after percutaneous interven-
tions.
NO donor drugs are a class of therapeutic agents that
bind a nitrate compound to another existing drug. Medi-
cations such as glyceryl trinitrate, isosorbide mononitrate,
and isosorbide dinitrate are NO donors used for anti-
anginal effects stemming from NO-mediated vasodilation.
This concept has been extended to other drugs in which a
nitrate group is attached to a pharmacologically active
compound. One of the more heavily investigated such
drugs is NO-releasing aspirin. The NO donor aspirin NCX-
4016 was used in a model of age-related recurrent stenosis,
and showed a marked reduction in intimal hyperplasia after
balloon injury compared with that in animals given aspirin
alone. These animals also had fewer gastrointestinal side
effects than did those given aspirin, although future com-
pounds using NO-donating nonsteroidal anti-inflamma-
tory compounds should limit this occurrence. NO-donating
aspirin also has antiproliferative effects, and increases
cGMP formation in saphenous vein grafts ex vivo, holding
promise as a potential tool for prevention of thrombosis
and intimal hyperplasia in vein grafts.
CONCLUSION
Without question, NO has a critical role in a variety of
cardiovascular diseases. Its production is crucial for main-
tenance of normal vascular endothelial integrity. A defi-
ciency of NO is a cardinal feature of atherosclerosis, intimal
hyperplasia, thrombosis, and aneurysm formation. As our
understanding of the complex biochemical features of NO
has evolved, its vasoprotective properties have been further
JOURNAL OF VASCULAR SURGERY
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over, we have come to appreciate the therapeutic possibil-
ities of NO, and that a number of common clinical thera-
pies produce their vasoprotective effects through
generation of NO. New technologies, such as gene therapy
and drug modification, will no doubt offer an even better
understanding of the biologic properties of NO and enable
application of NO to even more cardiovascular therapies.
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